Leveraging early stage discoveries for neurodegenerative diseases to reach faster clinical trial development

The goal of Anelixis is to help broker the transition between philanthropic investment in early stage discoveries and late stage clinical development. Anelixis plans to accomplish this goal by in licensing and validating early stage assets targeting neurodegeneration and bring them through proof of concept in patients. Anelixis’s committment to patients is find effective treatments that empower them to live productive and healthy lives